Advanced search
Add to list

Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

(2015) HAEMATOLOGICA. 100(suppl. 1). p.225-226
Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Stilgenbauer, S et al. “Phase I, First-in-human Trial of BI 836826 (an anti-CD37 Antibody) in Patients (PTS) with Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL).” Haematologica. Vol. 100. 2015. 225–226. Print.
APA
Stilgenbauer, S., Schleinitz, T. A., Hallek, M., Lang, F., Offner, F., Rossi, J.-F., Schroyens, W., et al. (2015). Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). HAEMATOLOGICA (Vol. 100, pp. 225–226). Presented at the 20th Congress of European Hematology Association.
Chicago author-date
Stilgenbauer, S, T Aurran Schleinitz, M Hallek, F Lang, Fritz Offner, J-F Rossi, W Schroyens, et al. 2015. “Phase I, First-in-human Trial of BI 836826 (an anti-CD37 Antibody) in Patients (PTS) with Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL).” In Haematologica, 100:225–226.
Chicago author-date (all authors)
Stilgenbauer, S, T Aurran Schleinitz, M Hallek, F Lang, Fritz Offner, J-F Rossi, W Schroyens, E Van Den Neste, L Ysebaert, P Blum, J Hocke, UU Kress, and T Zenz. 2015. “Phase I, First-in-human Trial of BI 836826 (an anti-CD37 Antibody) in Patients (PTS) with Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL).” In Haematologica, 100:225–226.
Vancouver
1.
Stilgenbauer S, Schleinitz TA, Hallek M, Lang F, Offner F, Rossi J-F, et al. Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). HAEMATOLOGICA. 2015. p. 225–6.
IEEE
[1]
S. Stilgenbauer et al., “Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL),” in HAEMATOLOGICA, Vienna, Austria, 2015, vol. 100, no. suppl. 1, pp. 225–226.
@inproceedings{7004483,
  articleno    = {abstract P589},
  author       = {Stilgenbauer, S and Schleinitz, T Aurran and Hallek, M and Lang, F and Offner, Fritz and Rossi, J-F and Schroyens, W and Van Den Neste, E and Ysebaert, L and Blum, P and Hocke, J and Kress, UU and Zenz, T},
  booktitle    = {HAEMATOLOGICA},
  issn         = {0390-6078},
  language     = {eng},
  location     = {Vienna, Austria},
  number       = {suppl. 1},
  pages        = {abstract P589:225--abstract P589:226},
  title        = {Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)},
  volume       = {100},
  year         = {2015},
}

Web of Science
Times cited: